Articles published by Boehringer Ingelheim

< Previous 1 2 Next >

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

October 02, 2023

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

September 14, 2023

From Boehringer Ingelheim

Via Business Wire

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

August 01, 2023

From Boehringer Ingelheim

Via Business Wire

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

July 25, 2023

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

May 10, 2023

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

May 09, 2023

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

March 29, 2023

From Boehringer Ingelheim

Via Business Wire

Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023

January 17, 2023

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 09, 2023

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim announces appointments to Board of Managing Directors

December 20, 2022

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia

December 19, 2022

From Boehringer Ingelheim

Via Business Wire

European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares

December 13, 2022

From Boehringer Ingelheim

Via Business Wire

University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs

October 20, 2022

From Boehringer Ingelheim

Via Business Wire

Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements

October 05, 2022

From Boehringer Ingelheim

Via Business Wire

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

August 03, 2022

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

July 06, 2022

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim signs Option to Acquire Trutino Biosciences

June 14, 2022

From Boehringer Ingelheim

Via Business Wire

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

June 02, 2022

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim launches RenuTend™: a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses

April 21, 2022

From Boehringer Ingelheim

Via Business Wire

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

April 05, 2022

From Boehringer Ingelheim

Via Business Wire

Award: Boehringer Ingelheim is Global Top Employer 2022

January 20, 2022

From Boehringer Ingelheim

Via Business Wire

EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements

November 11, 2021

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

October 27, 2021

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

October 26, 2021

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030

October 25, 2021

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

October 19, 2021

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

September 21, 2021

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

September 16, 2021

From Boehringer Ingelheim

Via Business Wire

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

August 03, 2021

From Boehringer Ingelheim

Via Business Wire

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

June 02, 2021

From Boehringer Ingelheim

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.